| Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy RGG Russell, NB Watts, FH Ebetino, MJ Rogers Osteoporosis international 19, 733-759, 2008 | 1836 | 2008 |
| Bisphosphonates: from the laboratory to the clinic and back again RGG Russell, MJ Rogers Bone 25 (1), 97-106, 1999 | 1701* | 1999 |
| Bisphosphonates: mechanisms of action H Fleisch, A Reszka, G Rodan, M Rogers Principles of bone biology, 1361-XLIII, 2002 | 1644 | 2002 |
| Nitrogen‐containing bisphosphonates inhibit the mevalonate pathway and prevent post‐translational prenylation of GTP‐binding proteins, including Ras SP Luckman, DE Hughes, FP Coxon, RGG Russell, MJ Dr. Rogers Journal of bone and mineral research 13 (4), 581-589, 1998 | 1573 | 1998 |
| Cellular and molecular mechanisms of action of bisphosphonates MJ Rogers, S Gordon, HL Benford, FP Coxon, SP Luckman, J Monkkonen, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2000 | 1351 | 2000 |
| Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates JE Dunford, K Thompson, FP Coxon, SP Luckman, FM Hahn, CD Poulter, ... The Journal of pharmacology and experimental therapeutics 296 (2), 235-242, 2001 | 1225 | 2001 |
| Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation … JE Fisher, MJ Rogers, JM Halasy, SP Luckman, DE Hughes, ... Proceedings of the National Academy of Sciences 96 (1), 133-138, 1999 | 947 | 1999 |
| New insights into the molecular mechanisms of action of bisphosphonates MJ Rogers Current pharmaceutical design 9 (32), 2643-2658, 2003 | 894 | 2003 |
| Molecular mechanisms of action of bisphosphonates: current status AJ Roelofs, K Thompson, S Gordon, MJ Rogers Clinical Cancer Research 12 (20), 6222s-6230s, 2006 | 739 | 2006 |
| Bone remodelling at a glance JC Crockett, MJ Rogers, FP Coxon, LJ Hocking, MH Helfrich Journal of cell science 124 (7), 991-998, 2011 | 710 | 2011 |
| The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs KL Kavanagh, K Guo, JE Dunford, X Wu, S Knapp, FH Ebetino, ... Proceedings of the National Academy of Sciences 103 (20), 7829-7834, 2006 | 678 | 2006 |
| Biochemical and molecular mechanisms of action of bisphosphonates MJ Rogers, JC Crockett, FP Coxon, J Mönkkönen Bone 49 (1), 34-41, 2011 | 633 | 2011 |
| Clodronate and liposome‐encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′‐(β, γ‐dichloromethylene) triphosphate, by mammalian cells in vitro JC Frith, J Mönkkönen, GM Blackburn, RGG Russell, MJ Rogers Journal of Bone and Mineral Research 12 (9), 1358-1367, 1997 | 630 | 1997 |
| Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti‐tumour activity CM Shipman, MJ Rogers, JF Apperley, RGG Russell, PI Croucher British journal of haematology 98 (3), 665-672, 1997 | 524 | 1997 |
| Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI‐298 FP Dr. Coxon, MH Helfrich, R Van't Hof, S Sebti, SH Ralston, A Hamilton, ... Journal of Bone and Mineral Research 15 (8), 1467-1476, 2000 | 485 | 2000 |
| Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite PP Lehenkari, M Kellinsalmi, JP Näpänkangas, KV Ylitalo, J Mönkkönen, ... Molecular pharmacology 61 (5), 1255-1262, 2002 | 479 | 2002 |
| Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL C Sobacchi, A Frattini, MM Guerrini, M Abinun, A Pangrazio, L Susani, ... Nature genetics 39 (8), 960-962, 2007 | 467 | 2007 |
| The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo LS Whyte, E Ryberg, NA Sims, SA Ridge, K Mackie, PJ Greasley, ... Proceedings of the national Academy of sciences 106 (38), 16511-16516, 2009 | 408 | 2009 |
| Overview of bisphosphonates MJ Rogers, DJ Watts, RGG Russell Cancer: Interdisciplinary International Journal of the American Cancer …, 1997 | 402 | 1997 |
| The pharmacology of bisphosphonates and new insights into their mechanisms of action RGG Russell, MJ Rogers, JC Frith, SP Luckman, FP Coxon, HL Benford, ... Journal of Bone and Mineral Research 14 (S2), 53-65, 1999 | 396 | 1999 |
